Technology‐Driven Decision Support for Opioid Tapering: A Scoping Review Authors: Laurits Valberg Hemmingsen, Lærke Karner Overgaard, Uffe Kock Wiil, Daniel Pilsgaard Henriksen Published: 2026 ABSTRACT ABSTRACTBackgroundGeneral practitioners manage most opioid tapering. This process requires time‐consuming, individualised planning accounting for patient preferences, dose options and costs. Consequently, clinicians need tools to support tapering. This review explores existing international digital decision support systems for opioid tapering.MethodsWe conducted a scoping review following the JBI methodology. Five databases (PubMed, Embase, CINAHL, Cochrane and Web of Science) were searched in January 2026. Title/abstract and full‐text screening were performed independently by two reviewers based on predefined eligibility criteria. Disagreements were resolved by a third reviewer. Data were extracted and summarised both descriptively and narratively.ResultsThe search identified 2340 studies, of which four met the eligibility criteria. The studies included described four different technology‐driven decision support tools for opioid tapering. The tools varied in format and clinical context (primary and secondary care), but they all aimed to support clinicians in planning and managing opioid tapering. Evidence on clinical effectiveness and real‐world implementation was limited across the studies.ConclusionOnly few studies have investigated technology‐driven decision support for opioid tapering, and only one is set within a European context. While tools exist in different formats and clinical settings, evidence on their effectiveness and real‐world implementation remains limited, highlighting a need for further development and evaluation. Introduction Opioids are a class of drugs that are used for treating pain, but long‐term opioid use is associated with numerous risks, including serious adverse effects and addiction [1]. Internationally, opioid deprescribing has received increasing attention, with recent clinical guidance emphasising the need for individualised, gradual dose reduction strategies across healthcare systems [2]. In Denmark, 394 800 people filled a prescription for opioids in 2023, compared with 446 200 in 2018, a decrease of 12% [1]. In the same period, total usage dropped from almost 33.8 million to 24.7 million morphine equivalents, marking a 27% reduction. These numbers indicate a positive development in terms of more cautious prescribing practices, reflecting increased political and clinical awareness [3]. However, approximately 119 000 Danes remain in long‐term opioid treatment (defined as use for more than 6 months) in 2023, which makes them the primary target group for opioid tapering efforts [1]. Clinical guidelines from the Danish Health Authority recommend considering tapering for patients with chronic non‐malignant pain after prolonged opioid use [4]. However, implementing tapering in clinical practice is often challenging, especially for patients on high doses or multiple opioids. The process involves individualised planning that ideally must consider numerous factors such as available formulations, package sizes, patient preferences and gradual dose reductions (often as low as 5%–10% per step) [4]. This above‐mentioned level of details in the tapering planning process requires repeated clinical consultations and ongoing patient motivation. Clinicians often face practical challenges such as limited availability of low‐dose formulations, inconvenient dose adjustments and the need for manual calculations and adjustments over time [5]. Additionally, tablet splitting and switching between opioids (e.g., from oxycodone to morphine) may be required, which further increase complexity. These challenges are compounded during transitions of care, where responsibility for opioid management is transferred between healthcare sectors, for example, from hospital to primary care following surgical procedures. Such transitions carry particular risk, as continuity of tapering plans may be lost and clinicians in the receiving sector may lack the information or tools needed to continue structured dose reductions. While these efforts are necessary for patient safety, they are also resource‐ and time‐consuming. General practice currently accounts for 88% of all prescriptions of medicines in Denmark [6]. At the same time, projections indicate that the number of people living with multimorbidity will reach 1.5 million by 2050 [7]. Together, these trends suggest that general practitioners will face increasing demands in managing complex medication regimens, including opioid tapering. Although conversion tools exist to support switching between different opioids, and simple tapering tools such as Excel‐based percentage calculators have been developed (without supporting scientific literature) [8, 9, 10], these solutions do not address the full complexity of individualised tapering plans. In response to capacity challenges, the 2024 report from the Danish Health Structure Commission highlights the need to explore technological tools to reduce administrative burdens and optimise healthcare [11]. Digital solutions are increasingly used in other clinical areas to support decision‐making and reduce manual workload [12]. Despite the complexity of opioid tapering, no such digital tool is currently available in the Danish healthcare system, and it leads to an interest in whether such solutions exist in other countries and what the effects of this might be. Such tools could potentially support healthcare professionals in the creation and implementation of tapering plans and calculations of doses. No other systematic literature reviews or scoping reviews were identified on this topic. Objective To address these issues, this scoping review aims to explore what types of technology‐driven decision support systems (DSS) for opioid tapering currently exist internationally, and how they have been used or evaluated. The following research question has been formulated: What technology‐driven decision support systems are available for opioid tapering, and how are they utilised? Methods This scoping review was conducted following the Joanna Briggs Institute (JBI) methodology for scoping reviews [13] and reported according to the Preferred Reporting Items for Systematic reviews and Meta‐Analyses—Scoping Review (PRISMA‐ScR) checklist [14] (Appendix 1). The review process included systematic searching, study selection based on predefined eligibility criteria and structured data extraction. Details of each step are described below. Information Sources and Search The search strategy was developed systematically to capture studies addressing technology‐driven decision support for opioid tapering. A search was conducted in five databases: PubMed, Embase, CINAHL, Cochrane and Web of Science. These databases were selected to ensure coverage of biomedical research, healthcare innovation and technology. The search was limited to peer‐reviewed literature. Grey literature sources such as industry reports, app store listings and non‐academic web content were not included. The search strategy was structured around three main conceptual blocks: medication, tapering and decision support/technology. Within each block, a brainstorming process was performed to generate a list of potentially relevant search terms. Terms were then prioritised into high, medium or low relevance categories, based on their alignment with the research question. To maintain a focused search, only the highly relevant prioritised terms were included in the final search string. The search strategy was conducted within title and abstract fields with no controlled vocabulary (e.g., MeSH terms) applied. Boolean operators (AND/OR) were used to combine concepts across the three blocks and truncation was used. No restrictions on study design or publication year were applied. The only limitation was language, as only studies published in English or Danish were included. The search string was adapted to the specific requirements of each database, as syntax and indexing can vary. An initial search was executed on 28 February 2025, followed by a verification search on 2 January 2026, to ensure the review captured the most current evidence. The search string applied was: (opioid* OR “morphine” OR “oxycodone” OR “tramadol”) AND (taper* OR dosing OR “dose reduction” OR deprescrib* OR “dose adjustment”) AND (“app” OR “software” OR “decision support” OR “mHealth” OR “eHealth” OR “telemedicine” OR “digital tool” OR “telehealth” OR “tele health” OR “tele medicine”). The search strategy was developed in consultation with an academic librarian at SDU. All identified records from both search periods were exported to Covidence [15]. Duplicates, including overlapping records between the initial and verification searches, were automatically removed by the software prior to screening. Eligibility Criteria The eligibility criteria were defined based on three elements derived from the research question. Included studies had to: 1focus on opioid tapering,2describe a technology‐based solution or decision support tool (e.g., app, web application or digital platform) as the intervention. Tools that did not target tapering directly but provided decision support for opioid dose calculations relevant to the tapering process (e.g., accurate dose adjustments during stepwise reductions) were also considered eligible. 1focus on opioid tapering, focus on opioid tapering, 2describe a technology‐based solution or decision support tool (e.g., app, web application or digital platform) as the intervention. Tools that did not target tapering directly but provided decision support for opioid dose calculations relevant to the tapering process (e.g., accurate dose adjustments during stepwise reductions) were also considered eligible. describe a technology‐based solution or decision support tool (e.g., app, web application or digital platform) as the intervention. Tools that did not target tapering directly but provided decision support for opioid dose calculations relevant to the tapering process (e.g., accurate dose adjustments during stepwise reductions) were also considered eligible. And studies were excluded if they: 3solely consisted of pain education for healthcare professionals or patients. 3solely consisted of pain education for healthcare professionals or patients. solely consisted of pain education for healthcare professionals or patients. Both patient‐facing and clinician‐facing tools were eligible, as both are considered relevant for supporting opioid tapering. Selection of Sources of Evidence Records were identified through database searches. After deduplication, two reviewers (LVH and DPH) independently screened at title and abstract level. Disagreements were resolved through discussion in a consensus meeting with a third reviewer (LKO). Following this, studies were selected for full‐text review using the same process, and disagreements at this stage were again resolved by consensus. The study selection process was illustrated in a PRISMA flow diagram (Figure 1). Study selection PRISMA flow chart. The articles excluded in the title and abstract screening process did not meet the eligibility criteria. Their reason for not meeting the eligibility criteria is not specified for this step. Data Charting and Items Data extraction was done in Microsoft Excel and was performed by LVH. The following predefined data items were extracted from each included study: title, author(s), year of publication, country of origin, aims/purpose, population/sample size, methods, intervention/technology, outcomes and key findings. Not all data items were relevant or reported in every study, and items were only extracted when appropriate. Synthesis of Results The results of this review were presented in two formats. First, a descriptive summary was provided in a structured table, organising key data according to type of purpose of study, study design, intended users and patients, type of technology and reported outcomes (Table 1). Second, the findings were synthesised narratively, offering an analysis across four categories. The categories will be introduced in the Results section. TABLE 1Descriptive summary of the included studies.Ref. #Author, year, and countryPurpose of studyStudy designIntended users and intended patient groupInterventionEvaluation[16] C. T. Matava, M. Bordini, A. Jasudavisius, C. Santos, M. Caldeira‐Kulbakas 2024 Canada To evaluate the effectiveness of a mobile app (PediPain) in reducing paediatric opioid dose calculation errors compared with traditional pocket calculator methodsRandomised controlled trial Intended users Secondary care providers Intended patient group Paediatric patients Clinical decision support Mobile app Dose calculation Error rate – 4.23% with PediPain – 30.9% in the control group Calculation time (median) – 48 s [IQR: 38–63] with PediPain – 69 s [IQR: 50–96] in the control group [17] B. Lai, D. Witt, T. Thacher, T. Witt 2020 USA To develop a software tool to support primary care providers in tapering chronic opioid therapy for chronic non‐cancer painFeasibility study Intended users Primary care providers Intended patient group Patients on chronic opioid therapy with chronic non‐cancer related pain Clinical decision support Web app Tapering No clinical outcomes were reported. Upcoming pilot study is intended.[18] M. Michel, J. Trafton, S. Martins, D. Wang, S. Tu, N. Johnson, M. K. Goldstein 2008 USA To design and test a clinical decision support system (ATHENA) integrated into the VA's EHR, to support safe opioid prescribing in chronic pain managementFeasibility study Intended users Primary care providers Intended patient group Not specified Clinical decision support EHR integrated tool Tapering No clinical outcomes were reported.[19] B. E. Hjaltadottir, A. B. Blöndal, Prescriby LLC Team, Orthopaedics Department Group, SÁÁ Group 2025 Iceland To investigate efficacy and safety of the Prescriby clinicExploratory cohort study Intended users Transitional service between primary and secondary care providers Intended patient group Patients in opioid treatment after knee or hip replacement surgery Clinical decision support Web and mobile app Tapering No clinical outcomes were reported. Upcoming publications of results will be presented in fourth quarter of 2026. Descriptive summary of the included studies. C. T. Matava, M. Bordini, A. Jasudavisius, C. Santos, M. Caldeira‐Kulbakas 2024 Canada Intended users Secondary care providers Intended patient group Paediatric patients Clinical decision support Mobile app Dose calculation Error rate – 4.23% with PediPain – 30.9% in the control group Calculation time (median) – 48 s [IQR: 38–63] with PediPain – 69 s [IQR: 50–96] in the control group B. Lai, D. Witt, T. Thacher, T. Witt 2020 USA Intended users Primary care providers Intended patient group Patients on chronic opioid therapy with chronic non‐cancer related pain Clinical decision support Web app Tapering M. Michel, J. Trafton, S. Martins, D. Wang, S. Tu, N. Johnson, M. K. Goldstein 2008 USA Intended users Primary care providers Intended patient group Not specified Clinical decision support EHR integrated tool Tapering B. E. Hjaltadottir, A. B. Blöndal, Prescriby LLC Team, Orthopaedics Department Group, SÁÁ Group 2025 Iceland Intended users Transitional service between primary and secondary care providers Intended patient group Patients in opioid treatment after knee or hip replacement surgery Clinical decision support Web and mobile app Tapering Results From the search in January 2026, a total of 2340 potentially relevant studies were found. After removing 1354 duplicates and screening 986 articles at title/abstract level, 12 articles were categorised as potentially relevant. After full text screening, four articles matched the eligibility criteria and thus included for data extraction [16, 17, 18]. The eight excluded studies were all assessed as having the wrong intervention, as they did not present a tool related to tapering. Descriptive Summary of the Studies Three of the four studies were conducted in Northern America—two in the United States and one in Canada. One study was conducted in Iceland. The articles include one RCT study, two feasibility studies and one exploratory cohort study. Table 1 provides an overview of the key characteristics of the four included studies. The table summarises study purpose, design, target users and patient groups, type of technology used and any reported evaluation. Narrative Summary of the Studies An analysis of the included studies was organised around four key narratives: (1) type of technology, (2) intended users and patient group, (3) intended use and (4) reported effects. Type of Technology The included studies each represent a different technological approach to supporting clinical decision‐making in relation to opioid use. Despite all being digital, the platforms and levels of system integration varied. One study [16] presented and evaluated PediPain, a stand‐alone mobile application designed for dose calculations of opioids for paediatric patients. Although PediPain was not designed specifically for tapering, it was included because accurate opioid dose calculation is a prerequisite for safe implementation of any tapering plan. Another study [17] developed a web‐based platform to assist care providers in creating individualised opioid tapering plans. This, also stand‐alone, tool offers adjustable parameters such as dose reduction percentages and frequency but does not integrate with other digital systems just like the PediPain app. In contrast, the third study [18] described ATHENA‐DSS, a decision support tool embedded in the EHR system used by the US Veterans Health Administration. This tool offers real‐time, guideline‐based recommendations on opioid prescribing, including tapering, during clinical encounters. The fourth study described the newly established Icelandic clinic Prescriby and their services regarding opioid tapering [19]. The described service is a dual module application. It has a web‐based clinician dashboard for creating and monitoring tapering plans corresponding to available medication strengths. It also has a mobile app for patients to give feedback on their experience with tapering. Both modules are compatible with Icelandic national EHR systems. Intended Users and Patient Group Although all four tools were designed to support healthcare professionals, they differ in terms of their targeted users and their intended patient group. The PediPain app [16] was developed for use in secondary care, specifically among anaesthesiologists and other perioperative staff involved in paediatric medication management. The target patient group was children receiving opioid treatment—described in the article as a group with high sensitivity to error. Both [17, 18] aimed to support primary care providers—taking into consideration that primary care is the setting where most long‐term opioid management and tapering typically occur. In Lai et al. [17], their tool was designed for clinicians treating adults with chronic non‐cancer pain. The tool assists in initiating and guiding individualised tapering strategies. Unlike the other two studies, Michel et al. [18] did not clearly define either the user role beyond ‘primary care’ or the specific patient group, which may reflect the tool's broader integration within an institutional system rather than targeting a specific clinical task. Hjaltadottir et al. [19] position the Prescriby clinic as a solution that bridges the primary and secondary healthcare sectors. While the current study specifically aims to recruit patients following hip and knee replacement surgery, the authors note that the service model is scalable to other patient populations requiring opioid management. By coordinating post‐discharge prescription responsibility, the clinic operates as a transitional care service between hospitals and primary care providers. Intended Use Across the four studies, the intended use of the digital tools varied in both scope and clinical function, but all aimed to support opioid‐related decision‐making processes. The most direct tapering support was described in Refs. [17, 18, 19], while the tool in Matava et al. [16], though not explicitly designed for tapering, offers functionality that may indirectly support such processes. Hjaltadottir et al. [19] introduced a dual‐module software designed to optimise opioid tapering. The system considers some of the practical constraints described, such as available medication strengths, to generate tapering schedules based on medication, entered starting dosage and treatment duration. Furthermore, the platform integrates a patient‐facing mobile application for remote monitoring, enabling clinicians to evaluate patient response and adjust the treatment if necessary. Lai et al. [17] presented a tool specifically developed to assist healthcare professionals in designing individualised opioid tapering plans. The tool allows clinicians to input parameters such as a patient's current dose, tapering duration and reduction frequency, thereby generating a tapering schedule tailored to clinical guidelines. It also includes features to adjust dose formulations and timing, supporting a gradual and structured reduction process. Michel et al. [18] described a broader clinical DSS integrated into the EHR, which includes guideline‐based recommendations for opioid prescribing in general. While the system is not limited to tapering, it supports clinicians in making decisions about opioid management, including titration, discontinuation, switching formulations or initiating new treatment plans. When tapering is part of the selected treatment plan, the tool provides detailed prescribing recommendations to guide the selection of specific opioids and appropriate dosing schedules. These recommendations are intended to reduce the risk of overdose, side effects and withdrawal symptoms. In addition, the system issues alert messages for potential drug allergies, further supporting patient safety. Matava et al. [16] did not target tapering specifically, but their app supports accurate opioid dose calculations for paediatric patients, including weight‐based adjustments and error prevention in complex dosing scenarios. In clinical tapering, such precision is essential to avoid overdosing or adverse events. In this sense, PediPain may serve a supportive role in tapering, especially in the implementation phase, where each dose change must be translated into a safe, age‐ and weight‐appropriate prescription. Reported Effects Only one of the included studies [16] reported formal evaluation results. In a randomised controlled trial, the PediPain app was tested against conventional pocket calculators, demonstrating an error rate of only 4.23% in dose calculations, compared with 30.9% in the control group. In addition, calculations were completed significantly faster using the app, with a median time of 48 s [IQR: 38–63] versus 69 s [IQR: 50–96] in the control group. These findings suggest that mobile tools for opioid dose calculation can enhance both safety and clinical workflow. Lai et al. [17] described their tapering tool in the context of a feasibility study, primarily describing its intended functions and application in primary care. While no clinical outcomes were reported, the authors stated that the software was intended for use in an upcoming pilot study. Hjaltadottir et al. [19] detailed a collaboration with the Department of Orthopedics at Landspítali University Hospital to investigate the safety and efficacy of Prescriby relative to usual care. While the current publication does not report clinical outcomes, the authors state that results from the clinical evaluation are expected to be published in the fourth quarter of 2026. Michel et al. [18] presented a DSS integrated into the EHR of the U.S. Veterans Health Administration. The focus was on system development and implementation, and no evaluation of its impact on prescribing behaviour or patient outcomes was provided. The level of evaluation thus varied considerably across studies—from a tested tool using an RCT design to conceptual or developmental prototypes without empirical outcome data. Discussion Summary of Evidence This scoping review aimed to explore the availability and use of technology‐driven decision support tools for opioid tapering. Four studies were identified, each describing a distinct digital tool designed to support clinicians in different aspects of opioid‐related care. Although limited in number, the studies demonstrate that such technologies exist in various forms ranging from mobile app dose calculators to web‐based tapering planners and EHR‐integrated tools. Clinical Stages of Tapering The tools were developed for different clinical contexts and target groups, but despite these differences, all tools shared the goal of supporting clinicians within fields of tapering and safe and structured opioid prescribing. Across the studies, decision support was provided at different stages of the clinical process: planning tapering schedules, executing accurate dose reductions, patient monitoring and embedding guideline‐based decisions into workflows. However, only one study [16] reported outcome data, highlighting a lack of evidence on clinical effectiveness, implementation feasibility and real‐world impact. Although the PediPain app demonstrated significantly fewer errors than conventional methods, an error rate of 4.23% still raises questions about reliability in high‐risk clinical settings. Hjaltadottir et al. [19] state that a follow‐up evaluation study will be published in the fourth quarter of 2026 and the forthcoming results may provide further evidence on clinical effectiveness. Moreover, Lai et al. [17] stated that a follow‐up pilot study was planned to evaluate the tool in clinical practice; no such study could be identified, which may indicate that the tool was not further developed or tested or still in process. The findings suggest that while technology‐driven support for opioid tapering is conceptually promising, its evidence of testing is still limited. Our findings align with broader evidence on clinical decision support for deprescribing. A recent systematic review of CDSS interventions targeting medication safety in older people found that while such systems can reduce potentially inappropriate prescribing, the overall evidence base remains limited and heterogeneous [20]. This suggests that the gap identified in the present review, between the availability of digital tools and the evidence for their effectiveness, is not unique to opioid tapering but reflects a wider challenge in the implementation of technology‐driven deprescribing support. Geographic Context and Transferability The majority of the identified tools were developed within North American healthcare systems, where clinical workflows, prescribing practices and healthcare financing differ substantially from publicly funded European systems. Hjaltadottir et al. [19] represent a notable exception, evaluating Prescriby within the Icelandic healthcare system. More broadly, the transferability of technology‐driven tapering tools across healthcare systems remains largely unexplored, and future studies should evaluate such tools in diverse clinical and organisational contexts. Limited Evidence Base and Future Directions The small number of included studies limits the generalisability of the findings but also emphasises the scarcity of published research in this area. Future studies should evaluate technology‐driven decision support for opioid tapering across a broader range of outcomes than prescribing metrics alone. Patient‐centred outcomes such as pain control, withdrawal symptoms, quality of life and patient satisfaction are essential to establish clinical value. Furthermore, implementation outcomes including clinician usability, workflow integration and adoption rates will be critical to determine whether such tools can be sustained in routine clinical practice. Limitations This scoping review has some limitations. Only peer‐reviewed studies were included; however, given the applied nature of this field, it is plausible that relevant tools exist in clinical practice or commercial settings without having been formally described or evaluated in academic publications. The exclusion of grey literature, including app store listings, industry white papers, and institutional reports, may therefore have contributed to the number of included studies. During the screening process, a substantial number of excluded records focused on patient education tools or opioid conversion calculators, which, although related, fell outside the scope defined by the review question. Additionally, the use of controlled vocabulary such as MeSH terms was not incorporated, which may have limited the sensitivity of the search in databases where such terms are supported. Furthermore, articles published after 2 January 2026 are not included. Conclusion This scoping review identified and analysed four peer‐reviewed studies describing technology‐driven decision support tools related to opioid tapering or opioid prescribing. The limited number of tools directly targeting technological solutions for tapering highlights a clear research and development gap. The included studies demonstrate that simple tools do exist in different technological formats and clinical contexts, but evidence of clinical effectiveness and real‐world use remains minimal. Funding This research received no specific grant from any funding agency in the public, commercial, or not‐for‐profit sectors. Ethics Statement According to Danish law, ethical approval is not required for scoping reviews. All data were obtained from publicly available sources. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Appendix 1 PRISMA checklist.